FOCAL POINTS (Courageous Discourse)

FOCAL POINTS (Courageous Discourse)

Share this post

FOCAL POINTS (Courageous Discourse)
FOCAL POINTS (Courageous Discourse)
Anaphylaxis-Induced Acute Coronary Syndrome Following COVID-19 mRNA-LNP Vaccination

Anaphylaxis-Induced Acute Coronary Syndrome Following COVID-19 mRNA-LNP Vaccination

Mechanisms of Kounis Syndrome and Therapeutic Rationale for Colchicine, Antihistamines, Steroids

Peter A. McCullough, MD, MPH's avatar
Peter A. McCullough, MD, MPH
Nov 03, 2024
∙ Paid
107

Share this post

FOCAL POINTS (Courageous Discourse)
FOCAL POINTS (Courageous Discourse)
Anaphylaxis-Induced Acute Coronary Syndrome Following COVID-19 mRNA-LNP Vaccination
14
21
Share
Upgrade to paid to play voiceover

By Peter A. McCullough, MD, MPH

The US CDC VAERS system as of October 4, 2024 has reported a record 36,753 severe allergic reactions (US/territories) including anaphylaxis which is a life-threatening reaction within a few minutes or hours after injection of a COVID-19 vaccine. Because there is a massive release of inflammatory factors commonly with an increase in heart rate and a fall in blood pressure, acute allergic reactions can trigger acute coronary syndromes otherwise known as heart attacks—cannoted by the eponym, Kounis syndrome. Zhao et al have published a systematic review concluding:

“Analysis of these data combined with known allergy-related mechanisms indicated that, regardless of the vaccine type, the first dose of the vaccine was more likely to cause Kounis syndrome than subsequent doses.”

Awaya et al have published a review on this catastrophic drug reaction:

Keep reading with a 7-day free trial

Subscribe to FOCAL POINTS (Courageous Discourse) to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Peter McCullough MD MPH
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share